TABLE 3

Treatment strategies and outcomes

Study (last name first author)TubbsCarringtonYousemAkiraTravisRyuBaloiraKawabataIndividual casesTotal
Treatment26/40 (65)21/23 (91)12/12 (100)31/31 (100)61/67 (91)151/173 (87)
 Removal of exposure4/27 (15)17/31 (55)6/61 (10)27/119 (23)
 Prednisolone21/23 (91)9/12 (75)31/31 (100)58/67 (86)119/133 (89)
 Other first/second line treatment3/12 (25)12/67 (18)15/79 (19)
Follow-up years3.1±2.89 (0.8–22)3.2±1.33.1±3.71.9 (0.8–5.8)8.25
Outcome
 Improvement7/14 (50)16/26 (62)14/25 (56)2/6 (33)1/19 (5)4/8 (50)30/31 (97)+37/66 (57)111/195 (57)
 Stable3/26 (11)3/25 (12)3/6 (50)12/18 (67)12/19 (63)2/8 (25)5/66 (8)37/168 (22)
 Worsened7/14 (50)7/26 (27)8/25 (32)1/6 (147)5/18 (28)1/19 (5)2/8 (25)5/14 (36)26/130 (20)
 Death1/18 (6)#5/19 (25)1/31 (3)14/66 (22)21/134 (16)
 Transplantation2/66 (3)2/66 (3)
 Relapse12/62 (18)12/62 (18)
PFT
 Normalised7/39 (18)7/39 (18)
 Improved6/9 (67)15/39 (38)16/48 (33)
 Stabilised1/9 (11)10/39 (26)11/48 (23)
 Deteriorated2/9 (22)7/39 (18)9/48 (19)

Data are presented as n/n (%), mean, mean±sd, or mean (range). Available data from case series and individual cases are presented. Totals data are summarised as percentages of available data. PFT: pulmonary function test; CT: computed tomography. #: patient committed suicide; : two patients died of cancer; +: five out of 14 patients with follow-up CT developed honeycombing during follow-up. Outcomes were not uniformly good as suggested by these data.